Your entry is only as good as your exit strategy...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TPST...$3.27... https://schrts.co/ZuBpTyYt ... 🥳...Bullish Harami Reversal Pattern on the Oversold Williams...
TPST...$3.27... https://schrts.co/ZuBpTyYt ... 🥳...Bullish Harami Reversal Pattern on the Oversold Williams...
I'm still blinking...🥳
Nope...🥳
NSAV...Trying to clear those .0127s here...🥳
NSAV...Trying to clear those .0127s here...🥳
Now we need triple the volume to take out .0006/0007...🥳
TKMO...0005s clearing here on 24Million Volume...🥳
Very easily...🥳
TKMO...0005s clearing here on 24Million Volume...🥳
That was in 2021...but wishful thinking...🥳
NSAV...0122...🥳...Big Block Ask at .0128...that goes down and .014 Breaks...imo...we shall see...Bullish Psar Flip on Friday with strong Accumulation and Money Flow...Lets see that .02 Breakout today...and Pink Current...
SPZI...Beauty Rig...🥳
NSAV...0122...🥳...Big Block Ask at .0128...that goes down and .014 Breaks...imo...we shall see...Bullish Psar Flip on Friday with strong Accumulation and Money Flow...Lets see that .02 Breakout today...and Pink Current...
Thank you...🥳
Thanks...I took 1 1/2 off from trading ...🥳...just started up again about 4 months ago ...trying to get the rust off...
NSAV ...012...🥳...riding the Upper Band watch for .014 Breakout...26 Million Volume ...
Yes Indeed...🥳NSAV ...012...riding the Upper Band watch for .014 Breakout...26 Million Volume ...
SGMO...5954...on the Upper Bollie Break...🥳
georgie18
Member Level
Re: georgie18 post# 380528
Friday, May 10, 2024 12:32:40 PM
Post#
380554
of 380567
SGMO...5605...Trying for Upper Bollie Breakout here...🥳
georgie18
Member Level
Re: None
Thursday, May 09, 2024 8:50:47 AM
Post#
380528
of 380553
SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”
The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.
Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.
SGMO...5954...on the Upper Bollie Break...🥳
georgie18
Member Level
Re: georgie18 post# 380528
Friday, May 10, 2024 12:32:40 PM
Post#
380554
of 380567
SGMO...5605...Trying for Upper Bollie Breakout here...🥳
georgie18
Member Level
Re: None
Thursday, May 09, 2024 8:50:47 AM
Post#
380528
of 380553
SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”
The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.
Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.
NSAV...0118s clearing here...Looking for .014 plus...🥳
georgie18
Member Level
Re: georgie18 post# 216475
Friday, May 10, 2024 4:05:10 PM
Post#
216518
of 216648
NSAV....0098...Beauty Close here...🥳Break/Hold .0104 on Monday and we see .014 plus...imo...we shall see...
georgie18
Member Level
Re: None
Friday, May 10, 2024 2:31:57 PM
Post#
216475
of 216513
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...
NSAV...0118s clearing here ...🥳
Yes it is...🥳
Thanks Rig…to you as well…🥳
NSAV....0098...Beauty Close here...🥳Break/Hold .0104 on Monday and we see .014 plus...imo...we shall see...
georgie18
Member Level
Re: None
Friday, May 10, 2024 2:31:57 PM
Post#
216475
of 216513
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...
NSAV....0098...Beauty Close here...🥳Break/Hold .0104 on Monday and we see .014 plus...imo...we shall see...
georgie18
Member Level
Re: None
Friday, May 10, 2024 2:31:57 PM
Post#
216475
of 216513
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...
NSAV...008s clearing here...🥳
NSAV...008s getting tapped on the 4 mill ask block...🥳
PRST...1661... https://schrts.co/gQwkQbDx ...Bands Choking the PPS...🥳
PRST...1661... https://schrts.co/gQwkQbDx ...Bands Choking the PPS...🥳
SGMO...5605...Trying for Upper Bollie Breakout here...🥳
georgie18
Member Level
Re: None
Thursday, May 09, 2024 8:50:47 AM
Post#
380528
of 380553
SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”
The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.
Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.
SGMO...5605...Trying for Upper Bollie Breakout here...🥳
georgie18
Member Level
Re: None
Thursday, May 09, 2024 8:50:47 AM
Post#
380528
of 380553
SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”
The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.
Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.
NSAV...0079...Hit .0085...HOD...Looking for .01 Break again...🥳
TKMO...0006...Went Pink Current Today...now can we get some volume please...🥳
georgie18
Member Level
Re: None
Wednesday, May 08, 2024 1:46:41 PM
Post#
380522
of 380551
TKMO...0006 off the .0004 dip...62 Million Volume...https://www.sec.gov/Archives/edgar/data/1946585/000121390024040692/ea0205547-1aw_tekumo.htm
Thanks…🥳
Nice…🥳
SGN...Thanks for the heads up Mark...🥳
We shall ses...🥳